Abiraterone ( DrugBank: Abiraterone )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
75	クッシング病	2
81	先天性副腎皮質酵素欠損症	3

75. クッシング病

臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03145285 (ClinicalTrials.gov)	April 18, 2017	26/4/2017	Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma	Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma	Cushing Syndrome;Adrenocortical Carcinoma	Drug: Abiraterone Acetate	Azienda Ospedaliera Spedali Civili di Brescia	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;Niguarda Hospital;San Camillo Hospital, Rome;San Luigi Gonzaga Hospital	Active, not recruiting	18 Years	N/A	All	10	Phase 2	Italy
2	EUCTR2016-000945-29-IT (EUCTR)	16/06/2016	04/11/2020	Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS)	Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) - ABACUS	Cushing’s syndrome in patients with adrenocortical carcinoma MedDRA version: 20.0;Level: PT;Classification code 10001388;Term: Adrenocortical carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]	Trade Name: ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE Product Name: ZYTIGA Product Code: [ZYTIGA] INN or Proposed INN: abiraterone acetato	AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Italy

81. 先天性副腎皮質酵素欠損症

臨床試験数 : 87 / 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03548246 (ClinicalTrials.gov)	January 2023	24/4/2015	Androgen Reduction in Congenital Adrenal Hyperplasia	A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency	Congenital Adrenal Hyperplasia	Drug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: Fludrocortisone	University of Texas Southwestern Medical Center	National Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los Angeles;Feinstein Institute for Medical Research	Withdrawn	2 Years	9 Years	All	0	Phase 2	United States
2	NCT02574910 (ClinicalTrials.gov)	August 1, 2017	24/4/2015	Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1	A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency	Congenital Adrenal Hyperplasia	Drug: Abiraterone acetate	University of Texas Southwestern Medical Center	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);University of Michigan;Children's Hospital Los Angeles	Active, not recruiting	2 Years	9 Years	All	36	Phase 1	United States
3	NCT01495910 (ClinicalTrials.gov)	December 2011	23/11/2011	A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	An Open-Label, Multiple-Dose, Dose-Finding Study of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	21-hydroxylase Deficiency	Drug: Abiraterone acetate	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	NULL	Completed	18 Years	N/A	Female	6	Phase 1	United States